drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR NK)
drug_description
Allogeneic CD19-directed CAR natural killer (NK) cell therapy; engineered NK cells recognize and kill CD19+ B-lineage cells via NK cytotoxicity to deplete autoreactive B cells/plasmablasts in SLE/LN.
nci_thesaurus_concept_id
C181804
nci_thesaurus_preferred_term
Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019
nci_thesaurus_definition
A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domain of OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK cells NKX019, these cells specifically target and bind to tumor cells expressing CD19. This induces secretion of pro-inflammatory cytokines and results in the lysis of CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that potentiates the immune response against tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf allogeneic NK cells engineered with a CD19-specific CAR (OX40 costimulatory domain and CD3ΞΆ signaling) and membrane-bound IL-15. The CAR targets CD19 on B-lineage cells, triggering NK cytotoxicity (perforin/granzyme) and cytokine release to lyse CD19+ cells, depleting autoreactive B cells/plasmablasts; mbIL-15 enhances NK survival and persistence.
drug_name
NKX019
nct_id_drug_ref
NCT06518668